In the study by Ren et al., the administration of the anti-IL-6 monoclonal antibody, tocilizumab, in a piglet model of Perthes disease significantly increased the bone volume and reduced the number of osteoclasts compared to those of the control group. Here, IL6 is linked to Legg-Calvé-Perthes disease.